Cresset and Redx Pharma have signed a major drug discovery collaboration, giving the latter access to Cresset's publicly available and proprietary computational chemistry technologies for use on its portfolio of drug discovery programs. In addition Cresset will provide consulting services in the area of candidate selection across a broad range of therapeutic areas and targets.
Rob Scoffin, CEO of Cresset, said: 'Cresset has developed an extensive range of consulting services around the critical areas of library design, compound design, virtual screening and lead optimisation. In this case we will initially be focusing our skills on helping Redx with their lead candidate selection process, while the collaboration also gives Redx the ability to access our expertise, in a very flexible manner, across the full range of computational drug discovery services.'
'Cresset is a valuable partner in our drug discovery programmes,' commented Dr Neil Murray, CEO of Redx Pharma. 'Their deep knowledge of computational chemistry and its application to drug discovery is enabling us to progress multiple projects across a wide range of target classes very quickly and cost-effectively.'
The Redx programs make use of a number of Cresset’s computational chemistry tools. In particular FieldTemplater and FieldAlign are used respectively to provide binding hypotheses and predictions of likely biological similarity for sets of molecules in various lead series.
